PTC Therapeutics: 2025 preliminary revenue ~$823M, Sephience $112M; 2026 guidance $700-800M product revenue

PTC THERAPEUTICS, INC.

2025-FY EPS reported $7.78 revenue$1,730,655,000

Preliminary 2025 total product & royalty revenue ~$823.4M, exceeding prior guidance; product revenue ~$587.8M.
Sephience (sepiapterin) net revenue $112.1M since launch, Q4 alone $92.5M; 946 patients on commercial therapy as of Dec 31.
Closed sale of remaining Evrysdi royalty to Royalty Pharma for $240M upfront plus up to $60M milestones; retains $150M milestone.
2026 guidance: product revenue $700-800M (19-36% YoY growth); GAAP R&D/SG&A $775-815M, non-GAAP $680-720M.
End-of-Phase 2 meeting for votoplam HD program; Phase 3 trial to start H1 2026; FDA open to Accelerated Approval.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.